These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 3544497)

  • 1. Evaluation of a new confirmatory assay for antibodies against lymphadenopathy-associated virus (LAV)/human T-lymphotropic virus type III (HTLV III).
    Abb J
    Vox Sang; 1986; 51(3):233-5. PubMed ID: 3544497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of acquired immunodeficiency syndrome (AIDS) retrovirus antibody by lymphadenopathy-associated virus (LAV) enzyme immunoassay in low- and high-risk populations.
    Ragni MV; Lewis JH; Bracken M; Toth R; Stokes J; Steffensen DO
    Transfusion; 1986; 26(3):299-301. PubMed ID: 3010516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Laboratory and epidemiologic evaluation of an enzyme immunoassay for antibodies to HTLV-III.
    Ward JW; Grindon AJ; Feorino PM; Schable C; Parvin M; Allen JR
    JAMA; 1986 Jul; 256(3):357-61. PubMed ID: 3014173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioimmunoassay and enzyme-linked immunoassay of antibodies to the core protein (P24) of human T-lymphotropic virus (HTLV III).
    Neurath AR; Strick N; Sproul P; Baker L; Rubinstein P; Stevens CE; Taylor P; Gallo RC; Gold JW; Lee YS
    J Virol Methods; 1985 May; 11(1):75-86. PubMed ID: 2989312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Importance of western blot analysis in predicting infectivity of anti-HTLV-III/LAV positive blood.
    Esteban JI; Shih JW; Tai CC; Bodner AJ; Kay JW; Alter HJ
    Lancet; 1985 Nov; 2(8464):1083-6. PubMed ID: 2865566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sera from HTLV-III/LAV antibody-positive individuals mediate antibody-dependent cellular cytotoxicity against HTLV-III/LAV-infected T cells.
    Rook AH; Lane HC; Folks T; McCoy S; Alter H; Fauci AS
    J Immunol; 1987 Feb; 138(4):1064-7. PubMed ID: 3027168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of screening as a preventive technology: the example of HTLV-III/LAV antibody testing.
    Ory HW; Koplan JP; Allen JR
    Isr J Med Sci; 1986; 22(7-8):524-8. PubMed ID: 3640749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How sensitive are the commercial assays for anti-HTLV III/LAV?
    Oldham LJ; Moulsdale HJ; Mortimer PP; Tedder RS; Morgan-Capner P
    J Med Virol; 1987 Jan; 21(1):75-9. PubMed ID: 3467026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HTLV-III/LAV infection in hemodialysis patients.
    Peterman TA; Lang GR; Mikos NJ; Solomon SL; Schable CA; Feorino PM; Britz JA; Allen JR
    JAMA; 1986 May; 255(17):2324-6. PubMed ID: 3007792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance evaluation of the Abbott HTLV III EIA, a test for antibody to HTLV III in donor blood.
    Barrett JE; Dawson G; Heller J; Bairstow C; Fico R; Webber JS; Gutierrez R; Decker RH
    Am J Clin Pathol; 1986 Aug; 86(2):180-5. PubMed ID: 3017089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-Hodgkin's lymphoma, HTLV-III/LAV, and HTLV-III/LAV antibody in the wife of a man with transfusion-acquired AIDS.
    Duncan ED; Miller HJ; McKeever WP
    Am J Med; 1986 Nov; 81(5):898-900. PubMed ID: 3640579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limitations of enzyme immunoassay tests for detection of HTLV-III/LAV antibodies.
    Lyons SF; McGillivray GM; Coppin AP; Schoub BD
    S Afr Med J; 1985 Oct; 68(8):575-6. PubMed ID: 2996159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human immunodeficiency virus antibody screening in blood donors from India, Nigeria and Thailand.
    Kühnl P; Seidl S; Ray V; Kulkarni AG; Mba EC; Chandanayingyong D
    Vox Sang; 1987; 52(3):203-5. PubMed ID: 3300027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [HIV (HTLV III/LAV) serology: experiences based on more than 42,000 tests].
    Gschnait F; Schmidt BL; Schwarz T; Heinz FX; Kunz C
    Wien Klin Wochenschr; 1987 Aug; 99(15):536-9. PubMed ID: 3310415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of an enzyme immunoassay for detection of antibody to human immunodeficiency virus in low risk populations.
    Peetoom F
    Transfusion; 1986; 26(6):536-8. PubMed ID: 3535179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of antibodies against LAV/HTLV III: comparative evaluation of four different commercial test kits.
    Abb J
    AIDS Res; 1986; 2(2):93-7. PubMed ID: 3013224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High prevalence and high titers of LAV/HTLV-III antibodies in healthy hemophiliacs in the midwestern United States.
    Goldsmith JC; Dewhurst S; Hedenskog M; Casareale D; Volsky DJ
    Am J Med; 1986 Oct; 81(4):579-83. PubMed ID: 3532787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies to human immunodeficiency virus (HTLV-III/LAV) in people from Lagos and Cross River States of Nigeria.
    Okpara RA; Akinsete I; Williams EE; Schneider J; Wendler I; Hunsmann G
    Acta Haematol; 1988; 79(2):91-3. PubMed ID: 3124480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An immunoglobulin G capture assay (GACRIA) for anti-HTLV III/LAV and its use as a confirmatory test.
    Parry JV
    J Med Virol; 1986 Aug; 19(4):387-97. PubMed ID: 3018141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radioimmunoassay and enzyme-linked immunoassay of antibodies directed against lymphadenopathy-associated virus (LAV) proteins larger than the core protein (P24).
    Neurath AR; Strick N; Lee YS; Nilsen T; Baker L; Sproul P; Rubinstein P; Taylor P; Stevens CE; Gold JW
    J Virol Methods; 1985 Oct; 12(1-2):85-92. PubMed ID: 3001122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.